XPENG Launches G9 SUV and P7 Sedan for Europe
3.2.2023 10:00:00 EET | Business Wire | Press release
XPENG (NYSE: XPEV and HKEX: 9868), today launched its two latest smart EV models for European markets: G9 flagship SUV, and the new P7 sports sedan. Both models, on show at eCar Expo in Stockholm Feb 3-5, are now available for order in Denmark, Norway, the Netherlands, and Sweden.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005580/en/
Premium electric smart sedan with sports car DNA (Photo: Business Wire)
“XPENG G9 and P7 bring a combination of superior styling, quality, performance and comfort, exemplifying our market-leading technology and innovation. Today also represents a significant milestone as we build our presence in Europe. We believe both vehicles deliver a new level of sophistication and a people-first mobility experience, and will be the electric vehicles of choice for many European customers,” said Brian Gu, Vice Chair and President of XPENG.
G9 features XPENG’s latest powertrain system, battery technology, and advanced driver assistance system (ADAS), fully complemented by a luxurious and immersive cabin experience. The new P7 - an upgraded version of P7 - combines its signature sports sedan profile with greater range, faster charging and a brand new smart cabin.
Faster Charging. Longer Range
XPENG’s new models bring some of the most powerful and advanced EV technology to Europe. XPENG G9 features a new powertrain system with 800 V Silicon Carbide (SiC) platform for ultra-fast charging of up to 300 kW, allowing drivers to add up to 100 km of range in just five minutes. This makes it possible to charge the 98 kWh battery from 10 % to 80% in just 20 minutes. G9 can travel up to 570 km WLTP on a single charge (RWD Long Range), exceptional for the battery size. G9 can be fitted with an electric tow bar, for up to 1,500 kg towed load, to suit European lifestyles.
The new P7 has been optimized with the maximum charging power of up to 175 kW, delivering fast charging from 10% to 80% in only 29 minutes. P7’s range has been improved, offering up to 576 km WLTP on a single charge (RWD Long Range). An electric tailgate and soft-closing doors are introduced for even greater comfort and convenience, along with a heat pump and heated steering wheel for more relaxing winter driving in the colder regions of Europe.
XPENG G9 and P7 are both engineered to meet E-NCAP five-star safety standards and stringent EU WVTA vehicle certification.
Superior Performance. Elegant Design
XPENG G9 and P7 boast superior performance with their advanced systems and elegant aerodynamic profiles, and are available in all-wheel-drive or rear-wheel drive configurations.
G9’s all-wheel drive version boasts up to 551 hp with a maximum torque of 717 Nm, powering acceleration from 0–100 km/h in just 3.9 seconds. The dual-chamber air spring system provides a wide range of stiffness adjustments to help the vehicle handle complex road conditions and ensure optimal ride comfort.
For the new P7, the all-wheel drive version accelerates from 0 to 100 km/h in just 4.1 seconds – outperforming even some sports car models. Brembo brakes also come as standard, giving drivers an extra level of control. All of this comes wrapped up in an exterior using XPENG's "Dynamic Aesthetics" design language that creates a more dynamic sports silhouette.
The new P7 is offered in a stunning range of colour styles, as well as an exclusive Wing Edition featuring scissors doors.
Both models adopt hidden door handles, with extremely low drag coefficients (0.236 for P7 and 0.272 for G9), for lower power consumption and extended range.
Comfort and Intelligence
The cabins of both vehicles use wraparound designs with high-quality finishing and materials to create a warm and comfortable environment. The ergonomically designed front seats feature heating and ventilation functions. To create an even more immersive cabin, both P7 and G9 can be configured with a Dynaudio sound system, producing up to 860 W and 2150 W respectively.
Both XPENG G9 and P7 come equipped with XPENG's proprietary Advanced Driver Assistance System, XPILOT, offering safety, driving, and parking support through a variety of smart functions. These functions are supported by 29 sensors including high-definition millimeter-wave radars, ultrasonic sensors, surround view and high perception cameras, enabling the vehicles to safely tackle multiple driving scenarios.
The upgraded in-car Xmart OS boasts a new 3D UI that supports English, Nederlands, Dansk, Norsk, and Svenska, depending on the market. Xmart OS also comes with the improved "Hey, XPENG" voice assistant, which can distinguish complex voice commands from all four zones of the cabin. These services are supported by wide infotainment screens and a library of in-car apps to assist, inform and entertain drivers and passengers.
G9 and P7 will also support easy and seamless over-the-air (OTA) updates that allow both software and firmware to be improved during normal use.
Expanding Service and Charging Networks
Delivery of the new models will capitalize on the opening of XPENG’s new Delivery and Service Centers in the key markets: at Lørenskog in Norway (opening February 2023), Badhoevedorp in the Netherlands, Stäket, Järfälla in Sweden and Hillerød in Denmark – all opening in the Q2 2023.
XPENG will also open additional authorized service locations with dedicated partners in key European countries by the end of 2023.
XPENG customers can access over 400,000 public charging stations in Europe, by collaboration with major European third-party charging operators and mobility service providers (Plugsurfing and Shell Recharge). With its new models, XPENG will provide third party home charger and installation services together with local partners, to offer customers a seamless easy charging experience.
Warranty
As a brand committed to product quality and offering better customer experiences, XPENG is proud to offer a five-year/120,000 km warranty* as standard for hassle-free ownership. For customers** ordering our new P7 sedan or G9 SUV between February 3 and December 31, 2023, the standard warranty will be extended to seven years/160,000 km from the date of delivery. This extended warranty is linked to the vehicle and is transferable when or if the vehicle is sold.
*For more information on the limited warranty policy, please refer to the warranty booklet.
**For more information on who is eligible for this extended warranty offer, please refer to the warranty booklet.
Pricing, Test Drive and Delivery
Expected starting prices* for the European version G9 are as follows
|
Model: |
XPENG G9 |
||
|
Version |
RWD Standard
|
RWD Long
|
AWD
|
|
Price(MSRP) - Norway (NOK) |
499 900 |
569 900 |
639 900 |
|
Price(MSRP) - Sweden (SEK) |
699 900 |
749 900 |
829 900 |
|
Price(MSRP) - Netherlands (EURO) |
57 990 |
61 990 |
71 990 |
|
Price(MSRP) - Denmark (DKK) |
479 900 |
549 900 |
599 900 |
Expected starting prices* for the new European version P7 are as follows
|
Model: |
XPENG P7 |
||
|
Version |
RWD Long Range |
AWD Performance |
Wing Edition |
|
Price(MSRP) - Norway (NOK) |
439 900 |
479 900 |
649 900 |
|
Price(MSRP) - Sweden (SEK) |
599 900 |
669 900 |
799 900 |
|
Price(MSRP) - Netherlands (EURO) |
49 990 |
59 990 |
69 990 |
|
Price(MSRP) - Denmark (DKK) |
399 900 |
479 900 |
599 900 |
*All prices include VAT and exclude local taxes, registration fees, and delivery costs. Please contact local XPENG representatives for details.
Deliveries for the new P7 will begin in June and G9 deliveries are expected to commence in September.
Customers can contact XPENG’s experience stores (Oslo, The Hague, Stockholm, Copenhagen) for test drive schedules. For more information about the G9 and P7, please visit the dedicated local XPENG websites:
https://heyxpeng.com/no/p7
https://heyxpeng.com/se/p7
https://heyxpeng.com/dk/p7
https://heyxpeng.com/nl/p7
https://heyxpeng.com/no/g9
https://heyxpeng.com/se/g9
https://heyxpeng.com/dk/g9
https://heyxpeng.com/nl/g9
Presskit (visual assets and specs) link
Follow us:
XPENG Twitter
XPENG LinkedIn
XPENG Facebook
XPENG Instagram
XPENG TikTok
XPENG YouTube
About XPeng Inc.
XPeng is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPeng is headquartered in Guangzhou, China. In 2021, the Company established its European headquarters in Amsterdam, along with other dedicated offices in Copenhagen, Munich, Oslo, and Stockholm. The Company’s Smart EVs are mainly manufactured at its plant in Zhaoqing, Guangdong province. For more information, please visit https://heyxpeng.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005580/en/
Contact information
For Media Enquiries:
Email: pr@xiaopeng.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
